Neurobiology of head neck squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2013.11.009

Abstract

Abstract: Neonatal nerves exist in tumor tissues, and tumor cells can invade nerve by neurogenesis. Current research shows that cancer cells can secrete cytokines to promote the differentiation and growth of nerve cells, in turn, the differentiation and growth of nerve cells can stimulate tumor development and metastasis. Neurogenesis is one way of interaction bettween tumor cells and microenvironment similar to angiogenesis and lymphangiogenesis, which has a major impact on biological behavior of tumor cells and prognosis.

Key words: Carcinoma, squamous cell, Neoplasm metastasis, Neurotrophic factors, Neurogenesis

YANG Rong, LU Wei, JI Tong. Neurobiology of head neck squamous cell carcinoma[J]. Journal of International Oncology, 2013, 40(11): 830-833.

References

［1］ Acloque H, Adams MS, Fishwick K, et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest, 2009, 119(6):1438-1449. ［2］ Benedito R, Rocha SF, Woeste M, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature, 2012,484(7392):110-114. ［3］ Mancino M, Ametller E, Gascon P, et al. The neuronal influence on tumor progression. Biochim Biophys Acta, 2011, 1816(2):105-118. ［4］ Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer: a review of the literature. Cancer, 2009, 115(15):3379-3391. ［5］ Monteiro-Amado F, Castro-Silva Ⅱ, Lima CJ, et al. Immunohistochemical evaluation of MMP-2, MMP-9 and CD31/microvascular density in squamous cell carcinomas of the floor of the mouth. Braz Dent J, 2013, 24(1):3-9. ［6］ Rahima B, Shingaki S, Saito C, et al. Prognostic signlficance of perineuraJ invasion in oral and oropharyngeal carcinoma. Oarl Surg Oral Med Oral Pathol 0ral Radiol Endod, 2004, 97(4):423-431. ［7］ Kosec A, Svetina L, Luksic I. Significance of clinical stage, extent of surgery and outcome in cutaneous squamous cell carcinoma of the head and neck. Int J Oral Maxillofac Surg, 2013, 42(1):82-88. ［8］ Dai H, Li R, Wheeler T, et al. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol, 2007, 38(2):299-307. ［9］ Soland TM, Brusevold IJ, Koppang HS, et al．Nerve growth factor receptor (p75 NTR)and pattern of invasion predict poor prognosis in oral squamous cell carcinoma．Histopathology, 2008, 53(1):62-72. ［10］ Kolokythas A, Cox DP, Dekker N, et al. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion?. J Oral Maxillofac Surg, 2010, 68(6):1290-1295. ［11］ Tsunoda S, Okumura L, Ito T. Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma. Br J Cancer, 2006, 95(3):322-330. ［12］ Dudas J, Bitsche M, Schartinger V, et al. Fibroblasts produce brain-derived neurotrophic factor and induce mesenchymal transition of oral tumor cells. Oral Oncol, 2011, 47(2):98-103. ［13］ Sasahira T, Ueda N, Yamamoto K, et al. Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma. Clin Exp Metastasis, 2013, 30(2):165-176. ［14］ Lee J, Jiffar T, Kupferman ME. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma. PLoS One, 2012, 7(1):e30246. ［15］ Scuteri A, Miloso M, Foudah D, et al. Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair?. Curr Stem Cell Res Ther, 2011, 6(2):82-92. ［16］ RicciVitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 2010, 468(7325):824-828. ［17］ Ito N, DeMarco RA, Mailliard RB, et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol, 2007, 81(1):75-83. ［18］ Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexiacachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care, 2004, 7(4):427-434. ［19］ Albo D, Akay CL, Marshall CL, et al. Neurogenesis in colorectal cancer is a marker of aggressive tumor behavior and poor outcomes. Cancer, 2011, 117(21):4834-4845. ［20］ Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invision: an investigatorblinded retrospective cohort study. Dermatal Surg, 2009, 35(12):1859-1866. ［21］ Huang SD, Yuan Y, Liu XH. Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas. BMC Cancer, 2009, 9: 9.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[7]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[10]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[11]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[12]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[13]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[14]	Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng. Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 83-88.
[15]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.